Gregory J Carven

US Patent:

20040248205, Dec 9, 2004

Filed:

Apr 14, 2004

Appl. No.:

10/823866

Inventors:

Lawrence Stern - Acton MA, US
Jennifer Stone - Arlington MA, US
Gregory Carven - Maynard MA, US
Sriram Chitta - Worcester MA, US
Iwona Strug - Worcester MA, US
Jennifer Cochran - Philadelphia PA, US

International Classification:

G01N033/53
C12M001/34

US Classification:

435/007100, 435/287200

Abstract:

This invention relates to arrays of immobilized major histocompatibility complex (MHC)-peptide complexes and methods for using them.

US Patent:

20100266617, Oct 21, 2010

Filed:

Jun 13, 2008

Appl. No.:

12/663950

Inventors:

Gregory John Carven - Maynard MA, US
Hans Van Eenennaam - Nijmegen, NL
Gradus Johannes Dulos - Elst, NL

International Classification:

A61K 39/395
C07K 16/18
C07H 21/04
C12N 15/63
C12N 5/10
C12P 21/00
A61P 35/00

US Classification:

4241721, 5303891, 5303873, 536 2353, 4353201, 435325, 435 696, 435375

Abstract:

Antibodies which block the binding of human Programmed Death Receptor 1(hPD-1) to its ligands (hPD-L1 or hPD-L2) and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune response through the PD-I pathway is also disclosed.

US Patent:

20210340238, Nov 4, 2021

Filed:

Jul 11, 2019

Appl. No.:

17/258908

Inventors:

- Cambridge MA, US
Thomas Schurpf - Cambridge MA, US
Allan Capili - Somerville MA, US
Stefan Wawersik - Westborough MA, US
Christopher Chapron - Watertown MA, US
Christopher Littlefield - Marblehead MA, US
Gregory J. Carven - Maynard MA, US
Kevin B. Dagbay - Brighton MA, US
Susan Lin - Boston MA, US
Justin W. Jackson - Cambridge MA, US
Caitlin Stein - Lebanon NH, US

International Classification:

C07K 16/22
A61P 13/12

Abstract:

Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGFβ1. Related compositions, methods and therapeutic use are also disclosed.

US Patent:

20210122814, Apr 29, 2021

Filed:

Jul 11, 2019

Appl. No.:

17/258771

Inventors:

- Cambridge MA, US
Allan Capili - Somerville MA, US
Thomas Schurpf - Cambridge MA, US
Constance Martin - Arlington MA, US
Kevin B. Dagbay - Brighton MA, US
Christopher Chapron - Watertown MA, US
Stefan Wawersik - Westborough MA, US
Christopher Littlefield - Marblehead MA, US
Gregory J. Carven - Maynard MA, US
Alan Buckler - Arlington MA, US
Susan Lin - Boston MA, US
Justin W. Jackson - Cambridge MA, US
Caitlin Stein - Lebanon NH, US
Andrew Avery - Lebanon NH, US
Anthony Cooper - White River Junction VT, US
Matthew Salotto - Hanover NH, US

International Classification:

C07K 16/22
A61K 45/06
A61P 35/00

Abstract:

Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGFβ1 with high potency. Related compositions, methods and therapeutic use are also disclosed.

US Patent:

20210101998, Apr 8, 2021

Filed:

Nov 24, 2020

Appl. No.:

17/102883

Inventors:

- New York NY, US
James R. Apgar - Newton MA, US
Zong Sean Juo - Cambridge MA, US
Macy Jin - Lexington MA, US
Mark Stahl - Lexington MA, US
Gregory J. Carven - Maynard MA, US
Matthew Holsti - Boston MA, US
Susan Benard - Melrose MA, US
Sunita R. Hett - Arlington MA, US
Reema Jasuja - Cambridge MA, US

International Classification:

C07K 16/38
A61K 39/00
A61K 39/395
A61K 38/48

Abstract:

The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.

US Patent:

20200231682, Jul 23, 2020

Filed:

Jul 27, 2018

Appl. No.:

16/634336

Inventors:

- Cambridge MA, US
Christopher Littlefield - Marblehead MA, US
Gregory J. Carven - Maynard MA, US
Abhishek Datta - Boston MA, US

International Classification:

C07K 16/28
C07K 16/22

Abstract:

Disclosed herein are inhibitors, such as antibodies, and antigen binding portions thereof, that selectively bind complexes of LTBP1-TGFβ1 and/or LTBP3-TGFβ1. The application also provides methods of use of these inhibitors for, for example, inhibiting TGFβ1 activation, and treating subjects suffering from TGFβ1-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGFβ1 inhibitor for a subject in need thereof are also provided.

US Patent:

20200190214, Jun 18, 2020

Filed:

Dec 17, 2019

Appl. No.:

16/716790

Inventors:

- New York NY, US
James R. Apgar - Newton MA, US
Zong Sean Juo - Cambridge MA, US
Macy Jin - Lexington MA, US
Mark Stahl - Lexington MA, US
Gregory J. Carven - Maynard MA, US
Matthew Holsti - Boston MA, US
Susan Benard - Melrose MA, US
Sunita R. Hett - Arlington MA, US
Reema Jasuja - Cambridge MA, US

International Classification:

C07K 16/38
A61K 39/00
A61K 39/395
A61K 38/48

Abstract:

The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.

US Patent:

20200181251, Jun 11, 2020

Filed:

May 9, 2018

Appl. No.:

16/611029

Inventors:

- Cambridge MA, US
Gregory J. Carven - Maynard MA, US
Stefan Wawersik - Westborough MA, US
Thomas Schurpf - Cambridge MA, US
Constance Martin - Arlington MA, US
Abhishek Datta - Boston MA, US
Mark Allen Farmer - North Reading MA, US

International Classification:

C07K 16/22
A61P 35/04
A61P 35/02

Abstract:

Disclosed herein are LRRC33 inhibiting agents and related methods and uses thereof. More specifically, therapeutic agents for inhibiting LRRC33 effects in vivo are provided. Such agents are useful for the treatment of various disorders involving cells expressing LRRC33 or LRRC33-containing complexes on the surface of cells.